Natco Pharma Limited has announced the allotment of equity shares through a Rights Issue to eligible shareholders. This move significantly impacts the shareholding pattern and the total equity capital of the company. Disclosures were made as per SEBI regulations concerning substantial acquisition of shares and insider trading. The rights issue was completed on 26/10/2026, with an effective date of allotment on 28/10/2026.
Natco Pharma Completes Rights Issue
Natco Pharma Limited has successfully completed its Rights Issue, leading to the allotment of equity shares to eligible shareholders. This significant corporate action, dated October 30, 2026, aligns with regulatory disclosures under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, and SEBI (Prohibition of Insider Trading) Regulations, 2015.
Impact on Shareholding and Capital
The rights issue has resulted in a substantial change in the shareholding patterns of various promoters, members of the promoter group, and other key stakeholders. Following the allotment, the total equity share capital of Natco Pharma has increased from 17,91,09,870 equity shares of Rs. 2/- each to 19,61,67,952 equity shares of Rs. 2/- each. This increase reflects the capital infusion and the expansion of the company’s equity base.
Key Allottees and Share Acquisition
Several individuals and entities have acquired shares through this rights issue, detailed in the accompanying disclosures. Notable acquisitions include:
- Venkaiah Chowdary Nannapaneni acquired 5,86,666 shares.
- Neelima Sita Nannapaneni acquired 2,55,387 shares.
- Rajeev Nannapaneni acquired 58,666 shares.
- Time Cap Pharma Labs Private Limited acquired 9,33,333 shares.
- Natsoft Information Systems Private Limited acquired 2,40,000 shares.
- Vistra ITCL India Limited A/C Neelima Nannapaneni Trust acquired 69,785 shares.
- Vistra ITCL India Limited A/C VCN Family Trust acquired 161 shares.
- Natco Aqua Limited acquired 1,523 shares.
- SAU Family Trust acquired 161 shares.
The mode of acquisition for these shares was through a Rights Issue, with the date of allotment advice/acquisition set for 26/10/2026 and the date of intimation to the company on 28/10/2026.
Post-Allotment Shareholding
Following the allotment, the shareholding percentages of several key entities have been updated. For instance, after the acquisition, Venkaiah Chowdary Nannapaneni holds 2,86,32,571 shares, representing 14.60% of the total diluted share capital. Similarly, Neelima Sita Nannapaneni now holds 4,38,347 shares (0.22%), and Rajeev Nannapaneni holds 11,36,666 shares (0.58%).
Other entities’ post-allotment holdings include Venkata Satya Swathi Kantamani with 1,59,94,673 shares (8.15%), Kantamaani Ratna Kumar with 54,761 shares (0.03%), Time Cap Pharma Labs Private Limited with 1,81,08,753 shares (9.23%), Natsoft Information Systems Private Limited with 1,60,24,900 shares (8.17%), Vistra ITCL India Limited A/C Neelima Nannapaneni Trust with 41,52,535 shares (2.12%), Vistra ITCL India Limited A/C VCN Family Trust with 1,861 shares (0.00%), Natco Aqua Limited with 17,523 shares (0.01%), and SAU Family Trust with 1,861 shares (0.00%).
Source: BSE
